SPC
LAB icon

Slate Path Capital’s Standard BioTools LAB Stock Holding History

Slate Path Capital’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,615,000
Closed -$1.48M – 44
2026
Q1 		$1.48M Hold
1,615,000
– – 0.02% 43
2025
Q4 		$2.07M Hold
1,615,000
– – 0.03% 50
2025
Q3 		$2.1M Hold
1,615,000
– – 0.03% 50
2025
Q2 		$1.94M Hold
1,615,000
– – 0.03% 42
2025
Q1 		$1.74M Hold
1,615,000
– – 0.03% 49
2024
Q4 		$2.83M Hold
1,615,000
– – 0.05% 50
2024
Q3 		$3.12M Hold
1,615,000
– – 0.05% 61
2024
Q2 		$2.86M Hold
1,615,000
– – 0.05% 56
2024
Q1 		$4.38M Buy
+1,615,000
New +$3.9M 0.09% 52

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Slate Path Capital's LAB Position: Q2 2026 in Review

Slate Path Capital sold out of Standard BioTools (LAB) in Q2 2026, closing a stake of 1,615,000 shares — an estimated $1.48M sold.

Slate Path Capital first reported a position in LAB in Q1 2024 and held it in 9 quarters. The position peaked at $4.38M in Q1 2024. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Slate Path Capital reported no remaining Standard BioTools position as of Q2 2026 after selling out during the quarter.
  • Slate Path Capital sold 1,615,000 Standard BioTools shares in Q2 2026, an estimated $1.48M.
  • Slate Path Capital first reported a position in Standard BioTools in Q1 2024 and held it in 9 quarters.
  • Slate Path Capital's Standard BioTools position peaked at $4.38M in Q1 2024.
  • 143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Slate Path Capital's 13F filing for Q2 2026, filed 14 Aug 2026.